{"id":7831,"date":"2021-06-25T05:41:39","date_gmt":"2021-06-25T05:41:39","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/"},"modified":"2021-06-25T05:41:39","modified_gmt":"2021-06-25T05:41:39","slug":"nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/","title":{"rendered":"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% dans les Emirats arabes unis par son partenaire Bausch + Lomb"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire mondial exclusif Bausch + Lomb, une soci\u00e9t\u00e9 leader mondial en sant\u00e9 oculaire de Bausch Health Companies Inc., a re\u00e7u l\u2019approbation de mise sur le march\u00e9 dans les Emirats arabes unis de VYZULTA<sup>\u00ae<\/sup> (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%.<\/p>\n<p>D\u00e9sormais approuv\u00e9 dans 12 pays, VYZULTA est commercialis\u00e9 aux Etats-Unis (2017), au Canada (2019), en Argentine (2020), au Mexique (2020), \u00e0 Hong Kong (2020) et \u00e0 Taiwan (2021). VYZULTA est approuv\u00e9 au Br\u00e9sil, en Colombie, au Qatar, en Cor\u00e9e du Sud, en Ukraine et dans les Emirats arabes unis. VYZULTA est indiqu\u00e9, aux Etats-Unis et dans d\u2019autres territoires, pour la r\u00e9duction de la pression intraoculaire chez les patients atteints de glaucome \u00e0 angle ouvert ou d&rsquo;hypertension oculaire. Bausch + Lomb poursuit la soumission de demandes d\u2019approbation dans des territoires o\u00f9 les donn\u00e9es cliniques de l\u2019enregistrement am\u00e9ricain peuvent \u00eatre utilis\u00e9es pour approbation par les autorit\u00e9s r\u00e9glementaires locales.<\/p>\n<p>Selon les termes de l\u2019accord de concession de licence exclusif avec Bausch + Lomb, Nicox re\u00e7oit des redevances croissantes de 6% \u00e0 12% sur les ventes nettes mondiales de VYZULTA et des paiements d\u2019\u00e9tape potentiels pouvant atteindre un montant de 150 millions de dollars<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire mondial exclusif Bausch + Lomb, une soci\u00e9t\u00e9 leader mondial en sant\u00e9 oculaire de Bausch Health Companies Inc., a re\u00e7u l\u2019approbation de mise sur le march\u00e9 dans les Emirats arabes unis de VYZULTA\u00ae (solution [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7831","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% dans les Emirats arabes unis par son partenaire Bausch + Lomb - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% dans les Emirats arabes unis par son partenaire Bausch + Lomb - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire mondial exclusif Bausch + Lomb, une soci\u00e9t\u00e9 leader mondial en sant\u00e9 oculaire de Bausch Health Companies Inc., a re\u00e7u l\u2019approbation de mise sur le march\u00e9 dans les Emirats arabes unis de VYZULTA\u00ae (solution [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-25T05:41:39+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% dans les Emirats arabes unis par son partenaire Bausch + Lomb\",\"datePublished\":\"2021-06-25T05:41:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\\\/\"},\"wordCount\":235,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\\\/\",\"name\":\"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% dans les Emirats arabes unis par son partenaire Bausch + Lomb - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2021-06-25T05:41:39+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% dans les Emirats arabes unis par son partenaire Bausch + Lomb - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% dans les Emirats arabes unis par son partenaire Bausch + Lomb - Nicox","og_description":"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire mondial exclusif Bausch + Lomb, une soci\u00e9t\u00e9 leader mondial en sant\u00e9 oculaire de Bausch Health Companies Inc., a re\u00e7u l\u2019approbation de mise sur le march\u00e9 dans les Emirats arabes unis de VYZULTA\u00ae (solution [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/","og_site_name":"Nicox","article_published_time":"2021-06-25T05:41:39+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/"},"author":{"name":"","@id":""},"headline":"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% dans les Emirats arabes unis par son partenaire Bausch + Lomb","datePublished":"2021-06-25T05:41:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/"},"wordCount":235,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/","url":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/","name":"Nicox : Approbation de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% dans les Emirats arabes unis par son partenaire Bausch + Lomb - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2021-06-25T05:41:39+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-dans-les-emirats-arabes-unis-par-son-partenaire-bausch-lomb-2\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7831"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7831\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}